
The world’s largest vaccine manufacturer, the Serum Institute of India (SII), will partner with CEPI (Coalition for Epidemic Preparedness Innovations) to develop a new vaccine targeting H5N1 avian flu as a prototype for Disease X, an as-yet-unknown pathogen with pandemic potential. The project will be supported by up to $16.4 million.
The vaccine will be developed on a baculovirus platform and will compare two H5 antigens for a recombinant protein vaccine: a wild-type and an artificial intelligence (AI)-optimized, broad-spectrum H5 antigen designed by scientists at Houston Methodist Research Institute.
Goal: Produce broad immune response
The goal is to produce a vaccine that elicits a broad immune response across multiple strains of H5 viruses. CEPI said the vaccine is a key part of its 100-day mission of accelerating vaccine development to within 100 days of identifying a pandemic threat.
This new project—which deepens our collaboration with SII, one of CEPI’s preferred vaccine manufacturing partners—is designed to power up global readiness.
“This new project—which deepens our collaboration with SII, one of CEPI’s preferred vaccine manufacturing partners—is designed to power up global readiness to tackle pandemic threats, from early-stage vaccine development through to global manufacture and supply,” said Richard Hatchett, MD, CEO of CEPI, in a press release.